BR112021021826A8 - Use of apremilast and a tyrosine kinase 2 inhibitor in the treatment of a disease or disorder responsive to phosphodiesterase type 4 inhibition - Google Patents

Use of apremilast and a tyrosine kinase 2 inhibitor in the treatment of a disease or disorder responsive to phosphodiesterase type 4 inhibition

Info

Publication number
BR112021021826A8
BR112021021826A8 BR112021021826A BR112021021826A BR112021021826A8 BR 112021021826 A8 BR112021021826 A8 BR 112021021826A8 BR 112021021826 A BR112021021826 A BR 112021021826A BR 112021021826 A BR112021021826 A BR 112021021826A BR 112021021826 A8 BR112021021826 A8 BR 112021021826A8
Authority
BR
Brazil
Prior art keywords
apremilast
inhibitor
inhibition
disease
treatment
Prior art date
Application number
BR112021021826A
Other languages
Portuguese (pt)
Other versions
BR112021021826A2 (en
Inventor
Gilles Buchwalter
Lisa Beebe
Mary Adams
Henry Schafer Peter
Robert Plenge
Te-Chen Tzeng
Tiffany Carr
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BR112021021826A2 publication Critical patent/BR112021021826A2/en
Publication of BR112021021826A8 publication Critical patent/BR112021021826A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

terapias combinadas compreendendo apremilaste e inibidores de tyk2. são fornecidos nesse documento métodos de tratamento de doenças e transtornos responsivos à inibição de pde4, compreendendo a administração de apremilaste e um inibidor de tyk2 a um indivíduo. também são fornecidas nesse documento composições farmacêuticas compreendendo apremilaste e um inibidor de tyk2.combination therapies comprising apremilast and tyk2 inhibitors. provided herein are methods of treating diseases and disorders responsive to pde4 inhibition, comprising administering apremilast and a tyk2 inhibitor to a subject. also provided herein are pharmaceutical compositions comprising apremilast and a tyk2 inhibitor.

BR112021021826A 2019-04-30 2020-04-30 Use of apremilast and a tyrosine kinase 2 inhibitor in the treatment of a disease or disorder responsive to phosphodiesterase type 4 inhibition BR112021021826A8 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2019/029772 WO2020222773A1 (en) 2019-04-30 2019-04-30 Combination therapies comprising apremilast and tyk2 inhibitors
PCT/US2020/030608 WO2020223431A1 (en) 2019-04-30 2020-04-30 Combination therapies comprising apremilast and tyk2 inhibitors

Publications (2)

Publication Number Publication Date
BR112021021826A2 BR112021021826A2 (en) 2022-01-04
BR112021021826A8 true BR112021021826A8 (en) 2022-06-21

Family

ID=66476870

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112021021809A BR112021021809A2 (en) 2019-04-30 2019-04-30 Combination therapies comprising apremilast and tyk2 inhibitors
BR112021021826A BR112021021826A8 (en) 2019-04-30 2020-04-30 Use of apremilast and a tyrosine kinase 2 inhibitor in the treatment of a disease or disorder responsive to phosphodiesterase type 4 inhibition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112021021809A BR112021021809A2 (en) 2019-04-30 2019-04-30 Combination therapies comprising apremilast and tyk2 inhibitors

Country Status (14)

Country Link
EP (2) EP3962475A1 (en)
JP (2) JP2022537877A (en)
KR (2) KR20220002488A (en)
CN (2) CN114269336A (en)
AU (2) AU2019443366A1 (en)
BR (2) BR112021021809A2 (en)
CA (2) CA3138473A1 (en)
CL (1) CL2021002847A1 (en)
CO (2) CO2021015622A2 (en)
IL (2) IL287665A (en)
MA (1) MA55799A (en)
MX (2) MX2021013317A (en)
SG (2) SG11202112043PA (en)
WO (2) WO2020222773A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL287665A (en) 2019-04-30 2022-07-01 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors
BR112023016590A2 (en) 2021-02-19 2023-11-14 Sudo Biosciences Ltd TYK2 INHIBITORS AND THEIR USES
CA3232812A1 (en) * 2021-09-23 2023-03-30 Ian MacQuarie CATLETT Methods of treating hair-loss disorders with tyk2 inhibitors
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US8367689B2 (en) * 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
AU2011328237A1 (en) 2010-11-09 2013-05-23 Cellzome Limited Pyridine compounds and aza analogues thereof as TYK2 inhibitors
CN103635188B (en) * 2011-04-28 2017-03-22 细胞基因公司 Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
PL2797581T3 (en) * 2011-12-27 2020-10-05 Amgen (Europe) GmbH Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
JP6109192B2 (en) 2012-01-10 2017-04-05 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Pyridazine amide compounds and their use as SYK inhibitors
EP2832734A4 (en) 2012-03-28 2015-08-26 Takeda Pharmaceutical Heterocyclic compound
EP2855451B1 (en) 2012-05-24 2017-10-04 Cellzome Limited Heterocyclyl pyrimidine analogues as tyk2 inhibitors
EP4071144A1 (en) * 2012-11-08 2022-10-12 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
CA2890935A1 (en) * 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn.alpha.
US9872854B2 (en) * 2013-03-14 2018-01-23 Celgene Corporation Methods for the treatment of psoriatic arthritis using apremilast
EP3029031A4 (en) 2013-07-30 2017-01-11 Takeda Pharmaceutical Company Limited Heterocyclic compound
CA2941824C (en) 2013-09-03 2020-08-25 Sareum Limited Substituted phenylamino-oxazole-4-carboxylic acid amides as tyk2 kinase inhibitors
AR094537A1 (en) 2013-11-07 2015-08-12 Bristol Myers Squibb Co PIRIDIL COMPOUNDS REPLACED WITH USEFUL ALQUILAMIDE AS MODULATORS OF THE ANSWERS OF IL-12, IL-23 AND / OR IFNa
WO2015089143A1 (en) 2013-12-10 2015-06-18 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
WO2015091584A1 (en) 2013-12-18 2015-06-25 F. Hoffmann-La Roche Ag Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors
WO2015123453A1 (en) 2014-02-14 2015-08-20 Portola Pharmaceuticals, Inc. Pyridazine compounds as jak inhibitors
CA2940666C (en) 2014-02-28 2022-08-23 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
EP3157520B1 (en) * 2014-06-23 2019-09-04 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
WO2016025686A1 (en) * 2014-08-15 2016-02-18 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
NO2721710T3 (en) 2014-08-21 2018-03-31
WO2016047678A1 (en) 2014-09-25 2016-03-31 武田薬品工業株式会社 Heterocyclic compound
TWI788655B (en) 2015-02-27 2023-01-01 美商林伯士拉克許米公司 Tyk2 inhibitors and uses thereof
US10023571B2 (en) 2015-09-02 2018-07-17 Nimbus Lakshimi, Inc. TYK2 inhibitors and uses thereof
CO2018008799A2 (en) 2016-02-24 2018-09-20 Pfizer Pyrazolo [1,5-a] pyrazin-4-yl derivatives as jak inhibitors
EP3523305B1 (en) 2016-10-07 2021-12-08 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
EP3526222B1 (en) 2016-10-14 2022-08-17 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
CN110114357B (en) 2016-10-28 2022-05-31 百时美施贵宝公司 Hetero-bicyclic compounds useful as modulators of IL-12, IL-23, and/or IFN alpha response
JP7012082B2 (en) 2016-11-17 2022-01-27 ブリストル－マイヤーズ スクイブ カンパニー Imidazopyridazine regulator of IL-12, IL-23 and / or IFN-alpha
GB2562702B (en) 2017-03-06 2022-05-18 Linear Shaped Ltd Frame and linear shaped charge
TWI783978B (en) * 2017-03-08 2022-11-21 美商林伯士拉克許米公司 Tyk2 inhibitors, uses, and methods for production thereof
IL287665A (en) 2019-04-30 2022-07-01 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors

Also Published As

Publication number Publication date
WO2020222773A1 (en) 2020-11-05
CN114206333A (en) 2022-03-18
EP3962476A1 (en) 2022-03-09
WO2020223431A1 (en) 2020-11-05
SG11202112043PA (en) 2021-11-29
CL2021002847A1 (en) 2022-07-22
CO2021015622A2 (en) 2022-02-28
AU2020266143A1 (en) 2021-12-02
JP2022537877A (en) 2022-08-31
IL287665A (en) 2022-07-01
IL287670A (en) 2021-12-01
MA55799A (en) 2022-03-09
BR112021021809A2 (en) 2022-01-04
SG11202112018YA (en) 2021-11-29
CA3138686A1 (en) 2020-11-05
JP2022537878A (en) 2022-08-31
MX2021013317A (en) 2022-01-18
CO2021015614A2 (en) 2021-12-10
CN114269336A (en) 2022-04-01
CA3138473A1 (en) 2020-11-05
KR20220002488A (en) 2022-01-06
BR112021021826A2 (en) 2022-01-04
EP3962475A1 (en) 2022-03-09
MX2021013318A (en) 2022-01-31
JP7453251B2 (en) 2024-03-19
KR20220002489A (en) 2022-01-06
AU2019443366A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
BR112021021826A8 (en) Use of apremilast and a tyrosine kinase 2 inhibitor in the treatment of a disease or disorder responsive to phosphodiesterase type 4 inhibition
PH12020500265A1 (en) Indole carboxamides compounds useful as kinase inhibitors
MX2021009246A (en) Immunomodulators, compositions and methods thereof.
CL2008001932A1 (en) Compounds derived from 6-cycloamino-3- (pyridin-4-yl) imidazo [1,2-b] pyridazine, cq1epsilon and / or ck1delta inhibitors; preparation procedure; pharmaceutical composition comprising them; and use in the treatment of sleep disorders, circadian rhythm disorder, cancer, and Alzheimer's disease.
EA202092154A1 (en) COMBINATION THERAPY
PH12020551425A1 (en) Rimegepant for cgrp related disorders
MX2017015574A (en) Inhibitors of bruton's tyrosine kinase.
UY30097A1 (en) THERAPEUTIC USES OF RTP801 INHIBITORS
WO2016109217A3 (en) Btk inhibitors
TN2017000158A1 (en) Carbazole derivatives
MX2021006619A (en) Tyrosine kinase inhibitors, compositions and methods there of.
BR112017016428A2 (en) "pharmaceutically acceptable compound or salt, pharmaceutical composition, use of a pharmaceutically acceptable compound or salt, and method for treating a malignant hyperproliferative disorder, an obesity associated metabolic condition, an autoimmune disorder or an inflammatory disorder";
MX2021004517A (en) Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof.
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
BR112021023110A2 (en) Methods of treating sjögren's syndrome with the use of a bruton tyrosine kinase inhibitor
CL2022001178A1 (en) tyk2 pseudokinase ligands
BR112022009710A2 (en) COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR
EA202191955A1 (en) MODIFIED RELEASE TABLET FORMULATIONS CONTAINING PHOSPHODIESTERASE INHIBITORS
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
NO20073104L (en) Use of a 5-HT6 Agonist for the Treatment and Prevention of Neurodegenerative Disorders
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
BR112021014566A2 (en) gpr35 modulators
MA39448A1 (en) (R) -pirlindole and its pharmaceutically acceptable salts for medical use
BR112021006424A2 (en) tyk2 kinase inhibitors
WO2019014322A8 (en) Kinase inhibitors for treatment of disease